CONTEXT: Mindfulness-based cognitive therapy (MBCT) is a group-based psychosocial intervention designed to enhance self-management of prodromal symptoms associated with depressive relapse. OBJECTIVE: To compare rates of relapse in depressed patients in remission receiving MBCT against maintenance antidepressant pharmacotherapy, the current standard of care. DESIGN:Patients who met remission criteria after 8 months of algorithm-informed antidepressant treatment were randomized to receive maintenance antidepressant medication, MBCT, or placebo and were followed up for 18 months. SETTING: Outpatient clinics at the Centre for Addiction and Mental Health, Toronto, Ontario, Canada, and St Joseph's Healthcare, Hamilton, Ontario. PARTICIPANTS: One hundred sixty patients aged 18 to 65 years meeting DSM-IV criteria for major depressive disorder with a minimum of 2 past episodes. Of these, 84 achieved remission (52.5%) and were assigned to 1 of the 3 study conditions. INTERVENTIONS: Patients in remission discontinued their antidepressants and attended 8 weekly group sessions of MBCT, continued taking their therapeutic dose of antidepressant medication, or discontinued active medication and were switched to placebo. MAIN OUTCOME MEASURE: Relapse was defined as a return, for at least 2 weeks, of symptoms sufficient to meet the criteria for major depression on module A of the Structured Clinical Interview for DSM-IV. RESULTS: Intention-to-treat analyses showed a significant interaction between the quality of acute-phase remission and subsequent prevention of relapse in randomized patients (P = .03). Among unstable remitters (1 or more Hamilton Rating Scale for Depression score >7 during remission), patients in both MBCT and maintenance treatment showed a 73% decrease in hazard compared with placebo (P = .03), whereas for stable remitters (all Hamilton Rating Scale for Depression scores ≤7 during remission) there were no group differences in survival. CONCLUSIONS: For depressed patients achieving stable or unstable clinical remission, MBCT offers protection against relapse/recurrence on a par with that of maintenance antidepressant pharmacotherapy. Our data also highlight the importance of maintaining at least 1 long-term active treatment in unstable remitters.
RCT Entities:
CONTEXT: Mindfulness-based cognitive therapy (MBCT) is a group-based psychosocial intervention designed to enhance self-management of prodromal symptoms associated with depressive relapse. OBJECTIVE: To compare rates of relapse in depressedpatients in remission receiving MBCT against maintenance antidepressant pharmacotherapy, the current standard of care. DESIGN:Patients who met remission criteria after 8 months of algorithm-informed antidepressant treatment were randomized to receive maintenance antidepressant medication, MBCT, or placebo and were followed up for 18 months. SETTING:Outpatient clinics at the Centre for Addiction and Mental Health, Toronto, Ontario, Canada, and St Joseph's Healthcare, Hamilton, Ontario. PARTICIPANTS: One hundred sixty patients aged 18 to 65 years meeting DSM-IV criteria for major depressive disorder with a minimum of 2 past episodes. Of these, 84 achieved remission (52.5%) and were assigned to 1 of the 3 study conditions. INTERVENTIONS:Patients in remission discontinued their antidepressants and attended 8 weekly group sessions of MBCT, continued taking their therapeutic dose of antidepressant medication, or discontinued active medication and were switched to placebo. MAIN OUTCOME MEASURE: Relapse was defined as a return, for at least 2 weeks, of symptoms sufficient to meet the criteria for major depression on module A of the Structured Clinical Interview for DSM-IV. RESULTS: Intention-to-treat analyses showed a significant interaction between the quality of acute-phase remission and subsequent prevention of relapse in randomized patients (P = .03). Among unstable remitters (1 or more Hamilton Rating Scale for Depression score >7 during remission), patients in both MBCT and maintenance treatment showed a 73% decrease in hazard compared with placebo (P = .03), whereas for stable remitters (all Hamilton Rating Scale for Depression scores ≤7 during remission) there were no group differences in survival. CONCLUSIONS: For depressedpatients achieving stable or unstable clinical remission, MBCT offers protection against relapse/recurrence on a par with that of maintenance antidepressant pharmacotherapy. Our data also highlight the importance of maintaining at least 1 long-term active treatment in unstable remitters.
Authors: David A Solomon; Andrew C Leon; Timothy I Mueller; William Coryell; Jedediah J Teres; Michael A Posternak; Lewis L Judd; Jean Endicott; Martin B Keller Journal: J Clin Psychiatry Date: 2005-03 Impact factor: 4.384
Authors: Willem Kuyken; Sarah Byford; Rod S Taylor; Ed Watkins; Emily Holden; Kat White; Barbara Barrett; Richard Byng; Alison Evans; Eugene Mullan; John D Teasdale Journal: J Consult Clin Psychol Date: 2008-12
Authors: Martin B Keller; Madhukar H Trivedi; Michael E Thase; Richard C Shelton; Susan G Kornstein; Charles B Nemeroff; Edward S Friedman; Alan J Gelenberg; James H Kocsis; David L Dunner; Robert M A Hirschfeld; Anthony J Rothschild; James M Ferguson; Alan F Schatzberg; John M Zajecka; Ronald D Pedersen; Bing Yan; Saeeduddin Ahmed; Jeff Musgnung; Philip T Ninan Journal: J Clin Psychiatry Date: 2007-08 Impact factor: 4.384
Authors: Peter J Bieling; Lance L Hawley; Richard T Bloch; Kathleen M Corcoran; Robert D Levitan; L Trevor Young; Glenda M Macqueen; Zindel V Segal Journal: J Consult Clin Psychol Date: 2012-03-12
Authors: Amanda J Shallcross; James J Gross; Pallavi D Visvanathan; Niketa Kumar; Amy Palfrey; Brett Q Ford; Sona Dimidjian; Stephen Shirk; Jill Holm-Denoma; Kari M Goode; Erica Cox; William Chaplin; Iris B Mauss Journal: J Consult Clin Psychol Date: 2015-08-10
Authors: Amanda J Shallcross; Emily C Willroth; Aaron Fisher; Sona Dimidjian; James J Gross; Pallavi D Visvanathan; Iris B Mauss Journal: Behav Ther Date: 2018-02-08